Pain
-
Seven patients diagnosed with erythromelalgia (EM) were investigated by microneurography to record from unmyelinated nerve fibers in the peroneal nerve. Two patients had characterized variants of sodium channel Nav1.7 (I848T, I228M), whereas no mutations of coding regions of Navs were found in 5 patients with EM. Irrespective of Nav1.7 mutations, more than 50% of the silent nociceptors in the patients with EM showed spontaneous activity. ⋯ The characteristic pattern of changes in conduction velocity observed in the patient with the I848T gain-of function mutation in Nav1.7 could be explained by axonal depolarization and concomitant inactivation of Nav1.7. If this were true, activity-dependent hyperpolarization would reverse inactivation of Nav1.7 and account for the supranormal CV. This mechanism might explain normal pain thresholds under resting conditions.
-
Being able to detect pain from facial expressions is critical for pain communication. Alongside identifying the specific facial codes used in pain recognition, there are other types of more basic perceptual features, such as spatial frequency (SF), which refers to the amount of detail in a visual display. Low SF carries coarse information, which can be seen from a distance, and high SF carries fine-detailed information that can only be perceived when viewed close up. ⋯ This general low-SF bias would seem an advantageous way of potential threat detection, as facial displays will be degraded if viewed from a distance or in peripheral vision. One exception was found, however, in the "pain-fear" task, where responses were not affected by SF type. Together, this not only indicates a flexible role for SF information that depends on task parameters (goal context) but also suggests that in challenging visual conditions, we perceive an overall affective quality of pain expressions rather than detailed facial features.
-
Tumor cells frequently metastasize to bone where they can generate cancer-induced bone pain (CIBP) that can be difficult to fully control using available therapies. Here, we explored whether PLX3397, a high-affinity small molecular antagonist that binds to and inhibits phosphorylation of colony-stimulating factor-1 receptor, the tyrosine-protein kinase c-Kit, and the FMS-like tyrosine kinase 3, can reduce CIBP. These 3 targets all regulate the proliferation and function of a subset of the myeloid cells including macrophages, osteoclasts, and mast cells. ⋯ Administration of PLX3397 was initiated on day 14 after prostate cancer cell injection when the tumor was well established, and tumor-induced bone remodeling was first evident. Over the next 6 weeks, sustained administration of PLX3397 attenuated CIBP behaviors by approximately 50% and was equally efficacious in reducing tumor cell growth, formation of new tumor colonies in bone, and pathological tumor-induced bone remodeling. Developing a better understanding of potential effects that analgesic therapies have on the tumor itself may allow the development of therapies that not only better control the pain but also positively impact disease progression and overall survival in patients with bone cancer.